PBC treatment Ocaliva leaves U.S. market amid safety concerns
Intercept Pharmaceuticals has voluntarily withdrawn Ocaliva (obeticholic acid), an oral therapy used to treat certain adults with primary biliary cholangitis (PBC), from…
News
Hormone-like therapy NF-1 shows promise in ICP mouse study
Nesfatin-1 (NF-1), a hormone-like molecule that may ease cellular stress, reduced injury to the placenta in a mouse model of intrahepatic cholestasis of pregnancy…
FDA weighs noninvasive biopsy alternative in MASH clinical trials
The U.S. Food and Drug Administration (FDA) will evaluate the use of Fibroscan, a noninvasive test, to replace liver biopsies in clinical trials for metabolic…
Virtual 5K expands annual run into national biliary atresia fundraiser
An annual fundraising run in the Washington area becomes a monthlong, virtual event this year to raise funds and awareness for the rare pediatric liver…
Phase 3 Trial of brelovitug for hepatitis D enrolls 1st patient
The first participant has been enrolled in a Phase 3 clinical trial testing Bluejay Therapeutics’ investigational therapy brelovitug against bulevirtide in adults with chronic…
Groups unite to fight liver disease during PBC Awareness Month
Members of the primary biliary cholangitis (PBC) community have come together in September as part of PBC Awareness Month to build support and share…
LSR gene mutations may cause new type of rare liver disease PFIC
Mutations in the LSR gene, including one previously unreported, were the likely cause of progressive familial intrahepatic cholestasis (PFIC) in two young children in Turkey,…
Alcohol consumption disrupts protein that controls liver fat: Study
Exposure to excessive alcohol disrupts the activity of a protein that plays a key role in keeping liver fat healthy, a study found. Researchers said…
New Alagille syndrome therapy named ART4 gets FDA designations
The U.S. Food and Drug Administration (FDA) has granted orphan drug and rare pediatric disease designations to ART4, an experimental therapy for Alagille syndrome…
Gene-editing approach may one day cure chronic hepatitis B: Study
A gene-editing therapy designed to specifically inactivate a hidden genetic blueprint of the hepatitis B virus (HBV) — the cause of hepatitis B —…
Recent Posts
- PBC treatment Ocaliva leaves U.S. market amid safety concerns
- When facing a hospital stay, pack a bag and hope for chocolate cake
- Hormone-like therapy NF-1 shows promise in ICP mouse study
- FDA weighs noninvasive biopsy alternative in MASH clinical trials
- Savoring the everyday moments that bring joy to our lives